Oral mucositis (OM) is a painful and debilitating side effect of many cancer treatments

Oral mucositis: an inflammation of mucous membranes in the oral cavity (mouth, gums, tongue), which usually appears as red, ulcer-like sores1,2

Oral mucositis is associated with oral pain and swelling, and development of oral mucositis may cause difficulty eating, swallowing, talking and sleeping. Oral mucositis may result in the need for opioids or other analgesics for pain management, lead to weight loss, and create a pathway for infection

Stomatitis is another word sometimes used to describe inflammation or sores of the mucus membranes inside the mouth.

OM incidence

In patients being treated for cancer, likelihood of experiencing OM varies by tumor type and treatment regimen.

By tumor type

Head and neck cancer receiving radiation therapy3

Hematopoietic stem cell transplant4

Breast cancer5

Head and neck cancer receiving chemotherapy5

Colorectal cancer5

Malignant lymphoma5
Non–small-cell lung cancer6

By targeted therapy




Additional targeted therapeutics associated with risk of OM include bevacizumab, cetuximab, erlotinib, gefitinib, and sorafenib.11

OM continues to be a problem for patients undergoing treatment for cancer.1,12 Management of OM should be considered for patients who face OM associated with treatment of cancer.1,12,13

The WHO Oral Toxicity Scale

The WHO (World Health Organization) classification of oral toxicity combines descriptions of mucosal changes, pain, and functionality into a single composite score.1,14,15

about mucositis

Indication and Important Safety Information

Indication: MuGard® Oral Mucoadhesive is indicated for the management of oral mucositis/stomatitis (that may be caused by radiotherapy and/or chemotherapy) and all types of oral wounds (mouth sores and injuries), including aphthous ulcers/canker sores and traumatic ulcers, such as those caused by oral surgery or ill-fitting dentures or braces.

Contraindications: MuGard is contraindicated in patients with known hypersensitivity to any of the ingredients in the formulation.

Special Precautions for Use: Patients should avoid eating or drinking for at least one hour after using MuGard. After use, patients should replace the bottle cap and tightly seal the bottle. This product should not be used after the expiration date shown on the carton and product label. Do not use this product in patients with known sensitivity to any of the product’s ingredients. Dilution of the product prior to use is not recommended.

You may report a MuGard® adverse event to Soleva Pharma at 877-319-7272 or by emailing to

Please see accompanying full Prescribing Information.